Upgrade to SI Premium - Free Trial

BioMarin (BMRN) PT Raised to $120 at Piper Jaffray

August 5, 2016 9:01 AM
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and lifted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles